BOTULINUM TOXIN TYPE A

Other

Brand names: DAXXIFY

Intramuscular

Mechanism of Action

12.1 Mechanism of Action DAXXIFY blocks neuromuscular transmission at the neuromuscular junction by inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein necessary for the successful docking and release of acetylcholine vesicles within nerve endings. Recovery of neurotransmission occurs gradually as the neuromuscular junction recovers from SNAP-25 cleavage and as new nerve endings are formed.

Indications

See full prescribing information

Contraindications

• 4 CONTRAINDICATIONS DAXXIFY is contraindicated in: patients with known hypersensitivity to any botulinum toxin preparation
• DAXXIFY
• DAXXIFY
• or any of the components in the DAXXIFY formulation. ( 4 ) Infection at the injection sites. ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS The potency units of DAXXIFY are not interchangeable with other preparations of other botulinum toxin products
2 , 11) Spread of toxin effects, swallowing and breathing difficulties can lead to death
1 ) Adverse event reports have been received involving the cardiovascular system with botulinum toxin products, some with fatal outcomes
7 ) Potential serious adverse reactions after administration of DAXXIFY for unapproved use

Known Side Effects

8 documented side effects by frequency

Drug Not Working

>10%

Headache

1-10%

Nausea

1-10%

Dizziness

0.1-1%

Fatigue

0.1-1%

Weakness

0.1-1%

Tingling/Numbness

0.1-1%

High Blood Pressure

0.1-1%

Community Discussions

No community discussions found for BOTULINUM TOXIN TYPE A yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intramuscular